Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy
{{output}}
Background: Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment for several mature B-cell malignancies. Reactivation of hepatitis B virus (HBV) is a well-described complication in patients with chro... ...
